Outcome of second- and third-lineHelicobacter pylorieradication therapies based on antimicrobial susceptibility testing | Zendy

Sarah Draeger | Zendy; Nicole Wüppenhorst | Zendy; Manfred Kist | Zendy; ErikOliver Glocker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Outcome of second- and third-lineHelicobacter pylorieradication therapies based on antimicrobial susceptibility testing

Author(s) -

Sarah Draeger,

Nicole Wüppenhorst,

Manfred Kist,

ErikOliver Glocker

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv223

Subject(s) - helicobacter pylori , clarithromycin , medicine , metronidazole , antimicrobial , regimen , antibiotics , urea breath test , breath test , rapid urease test , antibacterial agent , salvage therapy , gastroenterology , microbiology and biotechnology , biology , gastritis , chemotherapy , helicobacter pylori infection

The objective of this study was to assess the outcome of antimicrobial susceptibility-guided therapies in Helicobacter pylori-infected individuals who had undergone unsuccessful prior eradication treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research